Shionogi & Co., Ltd. (TYO:4507)
Japan · Delayed Price · Currency is JPY 3,040.00
-9.00 (-0.30%)
May 19, 2026, 1:45 PM JST
Shionogi & Employees
Shionogi & had 4,955 employees as of March 31, 2025. The number of employees decreased by 4 or -0.08% compared to the previous year.
Employees
4,955
Change (1Y)
-4
Growth (1Y)
-0.08%
Revenue / Employee
100.84M JPY
Profits / Employee
41.40M JPY
Market Cap
2.59T
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 4,955 | -4 | -0.08% |
| Mar 31, 2024 | 4,959 | -721 | -12.69% |
| Mar 31, 2023 | 5,680 | -13 | -0.23% |
| Mar 31, 2022 | 5,693 | 208 | 3.79% |
| Mar 31, 2021 | 5,485 | 263 | 5.04% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Takeda Pharmaceutical Company | 47,455 |
| Eisai | 10,917 |
| Toho Holdings | 7,609 |
| Towa Pharmaceutical | 4,788 |
| Tsumura & Co. | 4,272 |
| Sumitomo Pharma | 3,832 |
| Sawai Group Holdings | 3,310 |
| Nippon Shinyaku | 2,243 |
Shionogi & News
- 5 days ago - New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure - Business Wire
- 5 weeks ago - Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats - Business Wire
- 6 weeks ago - Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) - Business Wire
- 2 months ago - Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease - Business Wire
- 4 months ago - Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits - Reuters
- 2 years ago - Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease - Business Wire